The patent grant is a routine IP milestone with no near-term revenue implications. The key catalyst to watch is the upcoming Phase 3 data release for Annamycin later this quarter, which will determine the stock's direction. Monitor for that data and any financing needs disclosed in subsequent filings.
Price Chart
Executive Summary
Moleculin Biotech announced the issuance of a Hong Kong patent (No. 40073244) covering its proprietary method of reconstituting liposomal Annamycin, extending protection through June 25, 2040. The press release also notes that first Phase 3 clinical data for Annamycin is expected later this quarter, but the filing contains no financial data or guidance.
Key Facts
- Hong Kong patent No. 40073244 granted for method of reconstituting liposomal Annamycin, expires June 25, 2040
- Patent jointly owned with The University of Texas System
- Company expects first Phase 3 clinical data release later this quarter
- Global IP portfolio includes allowed/issued/granted patents in US, Australia, Canada, China, Europe, India, Israel, Japan, Mexico, Singapore, and Taiwan
- No financial data, revenue, earnings, or guidance provided in the filing
Financial Impact
No financial figures disclosed; patent extension has no immediate quantifiable revenue impact
Risk Factors
- Company requires significant additional financing with no commitments to conduct clinical trials
- Phase 3 data may fail to meet endpoints, wiping out any patent-related value
- Forward-looking statements about commercialization are aspirational and not guaranteed
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-015762 |
| Exhibit: ex_958659.htm | 0001437749-26-015762 |
| Document: 0001437749-26-015762-index-headers.html | 0001437749-26-015762 |
| Document: 0001437749-26-015762-index.html | 0001437749-26-015762 |
| Document: 0001437749-26-015762.txt | 0001437749-26-015762 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 6d ago | 8-K | $6.19 | awaiting T+20 | — | $7.09 (+14.46%) |
Oct 16, 2026 10d ago | 8-K | $0.2804 | awaiting T+20 | — | $7.09 (+2426.75%) |
Oct 9, 2026 16d ago | 8-K | $0.4139 | awaiting T+20 | — | $7.09 (+1611.77%) |
Oct 5, 2026 21d ago | 8-K | $0.4766 | awaiting T+20 | — | $7.09 (+1386.57%) |
Sep 29, 2026 27d ago | 8-K | $0.5264 | awaiting T+20 | — | $7.09 (+1245.93%) |
Sep 29, 2026 27d ago | Press Release | $0.5264 | awaiting T+20 | — | $7.09 (+1245.93%) |
Sep 28, 2026 28d ago | 8-K | $0.5690 | awaiting T+20 | — | $7.09 (+1145.17%) |
Sep 25, 2026 4w ago | 8-K | $0.6016 $6.50 | ▲ +980.45% | ▲ +981.93% | $7.09 (+1077.69%) |
Sep 23, 2026 4w ago | 8-K | $0.5279 $6.31 | ▲ +1095.30% | ▲ +1094.61% | $7.09 (+1242.11%) |
Sep 18, 2026 5w ago | 8-K | $0.5202 | awaiting T+20 | — | $7.09 (−1261.98%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers